Skip to content
Open access

Cerebral small vessel disease burden in late-onset epilepsy of unknown aetiology: insights from a prospective multicenter cohort.

Sep 2026 · Seizure · Vol 142, pp. 248-254 · 0 citations · 25 references
Medicine

Abstract

Background

Late-onset epilepsy of unknown aetiology (LOEU) represents a prevalent and often disabling neurological disorder. Existing studies indicate that cerebral small vessel disease (cSVD) may play a significant role in the pathogenesis of epilepsy within this population; however, prospective investigations are currently lacking. We aimed to systematically describe the burden and qualitative aspects of cSVD in a LOEU population.

Methods

Patients with LOEU were prospectively included across three university hospitals (Nancy, Lille and Reims, France). Patients were systematically assessed for clinical, cardiovascular, neurophysiological (EEG, polygraphy/polysomnography), neuropsychological, and radiological features (brain MRI and FDG-PET). cSVD was assessed using MRI only. A composite score evaluating WMH, microbleeds, EPVS, and lacunar infarcts was used. Moderate-to-severe cSVD was defined as a score of 2 4.

Results

A total of 55 patients were enrolled, predominantly male (63.6%), with a median age of 71yo (IQR 12.7) and multiple cardiovascular risk factors. Moderate-to severe cSVD was infrequent in this cohort (23.6%). No significant association was observed between cSVD score and epilepsy characteristics. Objective cognitive impairment was prevalent but was not associated with a higher burden of cSVD. Multivariate logistic regression identified advanced age as the sole significant factor associated with moderate-to-severe cSVD.

Conclusion

In this thoroughly characterized cohort, moderate-to-severe cSVD was infrequent, with age identified as the sole risk factor. These findings support the hypothesis that cSVD may serve as a biomarker of brain aging. Further research is required to substantiate these results.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.